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Abstract
Background: More than 30% of the world’s population are anemic with serious medical and economic consequences.
Red blood cell transfusion is the mainstay to correct anemia, but it is also one of the top five overused procedures and
carries its own risk and cost burden. Patient blood management (PBM) is a patient-centered and multidisciplinary
approach to manage anemia, minimize iatrogenic blood loss, and harness tolerance to anemia in an effort to improve
patient outcome. Despite resolution 63.12 of the World Health Organization in 2010 endorsing PBM and current
guidelines which include evidence-based recommendations on the use of diagnostic/therapeutic resources to provide
better health care, many hospitals have yet to implement PBM in routine clinical practice.
Method and results: A number of experienced clinicians developed the following “Simplified International
Recommendations for Patient Blood Management.” We propose a series of simple, cost-effective, best-practice,
feasible, and evidence-based measures that will enable any hospital to reduce both anemia prevalence on the day of
intervention/surgery and anemia-related unnecessary transfusion in surgical and medical patients, including obstetrics
and gynecology.
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Background
Patient blood management (PBM), refers to “the timely
application of evidence based medical and surgical con-
cepts designed to maintain hemoglobin concentration,
optimize hemostasis and minimize blood loss in an
effort to improve patient outcome” (Society for the
Advancement of Blood Management (SABM) 2014).
Thereby, PBM focuses on preservation of patient’s own
blood. It questions the dogma of red blood cell (RBC)
transfusion as the primary strategy for the treatment of
anemia but also supports the use of appropriate transfu-
sion practice in the hospitalized patient.
PBM should be performed by an institutionally
empowered multidisciplinary team considering three
most important principles: first, management of the
patient’s anemia, which mainly involves early detection
of anemia and utilizing nutritional and pharmaceutical
treatments to support erythropoiesis, if it is not mainly
genetic-related; second, the use of interdisciplinary blood
conservation measures to reduce iatrogenic blood loss,
including prevention and proactive management of co-
agulopathy, precise anesthetic and surgical techniques,
intra- and postoperative autologous blood conservation
techniques, and minimization of phlebotomy volume
and frequency; and third, harness tolerance to anemia
and patient-centered decision-making to allow optimal
blood use involving thorough communication with the
patient about the risks and benefits of the various poten-
tial interventions (Society for the Advancement of Blood
Management (SABM) 2014; Goodnough et al. 2013;
Spahn and Goodnough 2013).
Considerable scientific evidence indicates that PBM
reduces perioperative blood loss and transfusion needs
(Leahy et al. 2017; Gross et al. 2015; Goodnough et al.
2014a; Goodnough et al. 2014b; Moskowitz et al. 2010;
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Oliver et al. 2014; Theusinger et al. 2014; Leahy et al. 2014;
Roubinian et al. 2014; Meybohm et al. 2016a), perioperative
morbidity (Leahy et al. 2017; Gross et al. 2015; Moskowitz
et al. 2010; Meybohm et al. 2016a), mortality (Leahy et al.
2017; Goodnough et al. 2014a; Moskowitz et al. 2010),
length of hospital stay (Goodnough et al. 2014a; Moskowitz
et al. 2010), and costs (Leahy et al. 2017; Trentino et al.
2015). In this respect, the WHO has officially been ur-
ging member states to implement PBM since 2010
(WHA63.12). There exist also a number of guidelines
and standards from professional associations providing
detailed evidence-based information and recommenda-
tions on PBM in Australia, the USA, and in several
European countries (Society for the Advancement of
Blood Management (SABM) 2014; National Blood
Authority Australia; Joint United Kingdom (UK) Blood
Transfusion and Tissue Transplantation Services Profes-
sional Advisory Committee 2014; American Society of
Anesthesiologists Task Force on Perioperative Blood
Management 2015; Government of Western Australia
Department of Health; Kozek-Langenecker et al. 2013a;
Leal-Noval et al. 2013; Kozek-Langenecker et al. 2013b;
Hunt et al. 2015; AABB 2014; NHS Blood and Transplant;
AABB 2015; Klein et al. 2016). However, many barriers
limit the translation of PBM into clinical practice world-
wide (Munoz et al. 2015; Fischer et al. 2015; Vamvakas
2013; Mbanya 2012). These include clear guidance on
clinical pathways, lack of knowledge, lack of interdisciplin-
ary commitment, lack of resources, and concerns about
risks. In a recent paper (Meybohm et al. 2017), we provided
comprehensive bundles of PBM components encompassing
more than 100 different PBM measures to facilitate a step-
wise implementation process of the most feasible measures.
The aim of this current opinion-based document is to
provide clinicians with a working template to start or
improve the implementation of PBM practices, specific-
ally through the implementation of simplified recom-
mendations developed with reference to existing best
practice guidelines and appropriate key literature on
blood transfusion.
Methods
Experts in PBM were consulted in order to provide con-
sensus on key simple recommendations for the imple-
mentation of PBM based on their current practice and
experience in Australia, Europe, and the USA. The selec-
tion of the authors was intended but covered experts
who have been involved in developing a European Guide
on Good Practices for Patient Blood Management
(P.M., K.Z.), international consensus on the perioperative
management of anemia and iron deficiency (P.M., A.A.K.,
M.M., T.R., A.S., D.R.S.), National Institute for Health and
Care Excellence Guidance on blood transfusion (M.F.M.)
(Padhi et al. 2015), and landmark papers in the field of
PBM (B.F., L.T.G., A.S.). Level of evidence was assigned to
each recommendation (level A, multiple randomized clin-
ical trials or meta-analyses; level B, single randomized trial
or non-randomized studies; level C, consensus opinion of
experts, case studies, or standard-of-care). All authors
were asked to vote point-by-point for each recommenda-
tion (agreed/not agreed/abstention). If a statement did not
achieve 80% or more of the votes, the statement under-
went further revision and then entered again into the
online voting process. The consensus of recommendation
is shown in Table 1.
We would like to stress that this paper contains the
authors’ independent opinions based on experience, as
well as evidence-based practices supported by clinical
studies. No pharmaceutical company has funded the
development or writing of the manuscript.
Simplified International Recommendations for the
Implementation of Patient Blood Management
(SIR4PBM)
Comprehensive project management
Each hospital should appoint key leaders for PBM project
management (this could be a physician, a nurse, or the in-
stitution’s patient safety officer), who should have a central
role in charge of communication, education, and docu-
mentation. Communication should involve the following
stakeholders: chief medical officer, chief executive officer,
surgeons, anesthesiologists, intensive care specialists,
nurses, transfusion medicine specialists, transfusion com-
mittee, gastroenterologists, hematologists, cardiologist,
general practitioners, finance administrative and quality
management personnel, central laboratory, information
technology department, and patients’ representatives
(level C).
PBM-related metrics and blood usage should be col-
lected to monitor implementation success and allow
identification of potential areas for improvement. PBM-
related metrics should include proportion of patients
who are anemic and receive treatment, use of blood con-
servation techniques, and use of hemostatic products
and blood components. Data should be audited at ward,
specialty, and divisional level with regular feedback to all
hospital staff. Further consideration should be given for
these metrics to be utilized as a quality improvement
marker for appraisal of staff groups (level C).
Education program
In clinical areas, such as preoperative clinic/preadmis-
sion testing units, operating room, and intensive care
unit, PBM education initiatives need to be addressed
with physicians and nurses. Standard operating proce-
dures, clinical protocols, visual aids, and checklists are
crucial. They should include outpatient and preoperative
protocols and ward-based transfusion algorithms. Also,
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training on the use of available massive hemorrhage pro-
tocols should be provided (level C). These massive
hemorrhage protocols including specific coagulation and
transfusion algorithms for postpartum, trauma, transplant,
or cardiac surgery should be in place and encourage early
detection, definitive intervention, and treatment of acute
hemorrhage (Kozek-Langenecker et al. 2013a; Hunt et al.
2015; Kozek-Langenecker 2014; Spahn et al. 2013;
Rossaint et al. 2013) (level C). A mandatory online PBM
e-learning course may further underpin education initia-
tives (Meybohm et al. 2016b; National Service Scotland;
BloodSafe eLearning Australia) (level C). Ideally, educa-
tion on PBM should be initiated among undergraduates at
medical schools and continued at hospital level (level C).
Diagnosis and treatment of preoperative anemia
Preoperative screening includes evaluation and manage-
ment of anemia. From a practical point of view, patients
scheduled for surgical procedures with expected blood
loss (>500 ml) or a ≥10% probability of RBC transfusion
should be identified and assessed at the earliest op-
portunity and be screened for iron deficiency and other
likely causes of anemia (Government of Western Australia
Department of Health; AABB 2014; National Service
Scotland; Carless et al. 2010; Goodnough and Schrier
2014; Shah et al. 2015; Muñoz et al. 2017) (level B). Serum
ferritin level <30 ng/ml, transferrin saturation <20%, and/
or microcytic hypochromic red cells (mean corpuscular
volume <80 fl; mean corpuscular hemoglobin <27 pg) are
indicative of iron deficiency. In the presence of inflamma-
tion or transferrin saturation <20%, a ferritin >100 ng/ml
points to functional iron deficiency (iron sequestration).
The availability of an easy-to-follow, diagnostic algorithm
is desirable (Goodnough and Schrier 2014; Muñoz et al.
2017). Intravenous iron is efficacious and safe (Auerbach
and Macdougall 2014) and should be used in patients in
whom oral iron is not tolerated or if surgery is planned in
less than 4–6 weeks after the diagnosis of iron deficiency
(Shander et al. 2014a; Froessler et al. 2016; Bisbe et al.
2011; Munoz et al. 2014) (level B). Erythropoiesis-
Table 1 Summary of the simplified recommendations with level of evidence (LoE) and consensus of recommendation (CoR)
Recommendations LoE CoR (%)
1. Comprehensive project management
Key leaders; involvement of stakeholders C 100
Collection of PBM-related metrics C 90
2. Education program
Education initiatives; standard operating procedures, clinical protocols, visual aids, checklists; algorithms C 100
Massive hemorrhage protocols; coagulation and transfusion algorithms C 100
Online PBM e-learning course C 100
Education at medical schools and hospital level C 100
3. Diagnosis and treatment of preoperative anemia
Preoperative screening, diagnosis, and treatment of anemia B 100
Intravenous iron if oral iron is not tolerated or if surgery <4–6 weeks B 100
Erythropoiesis-stimulating agents if nutritional deficiencies have been ruled out, corrected, or both B 100
Elective surgery should be postponed until preoperative anemia has been classified and treated, if possible C 100
4. Reduction of iatrogenic diagnostic-/surgery-related blood loss
Avoiding unnecessary laboratory tests, lower frequency of sampling, using the smallest collection tube size C 100
Closed in-line flush blood sampling devices for arterial (and central) lines B 100
Appropriate cessation strategies for anticoagulation and antiplatelet therapy C 100
Intraoperative approaches (meticulous hemostasis, minimally invasive surgery, laparoscopic surgery, diathermy dissection,
physicians’ mindfulness regarding limiting blood loss, topical hemostatic agents)
B 100
Coagulation algorithm (preoperative assessment, ensuring basic conditions for hemostasis, reversal of anticoagulants,
point-of-care diagnostics, optimized coagulation management, use of clotting factor concentrates)
B 100
Tranexamic acid A 100
Autologous blood cell recovery (cell salvage) A 100
5. Optimal blood component use with patient-centered clinical decision support
Physician order entry with clinical decision support B 100
Patient’s informed consent prior transfusion; hand-written/computer-generated forms with detailed outline of transfusion
benefits, risks, and alternatives; information in discharge summary; patient’s own preferences
C 80
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stimulating agents might be suggested for anemic patients
in whom nutritional deficiencies have been ruled out, cor-
rected, or both (Goodnough et al. 2011; Voorn et al. 2016;
Weltert et al. 2015) (level B). Elective surgery should be
postponed until preoperative anemia has been appropri-
ately classified and treated, if possible (level C).
Reduction of iatrogenic diagnostic-/surgery-related
blood loss
Blood loss associated with invasive laboratory testing can
either cause or aggravate hospital-acquired anemia which
is associated with increased length of stay and complica-
tions (Koch et al. 2015). Blood testing should not be
“routined” but informed. Reduction of blood drawn for
laboratory analyses can be achieved by avoiding unneces-
sary laboratory tests and lower frequency of sampling
(Raad et al. 2016) and using the smallest collection tube
size that is practical for the required analysis, which is
often pediatric-size bottles (level C). However, there are
several difficulties with these bottles (e.g., overfill and
underfill of tubes, large IT labels not fitting on small
tubes, issues with the bottles not fitting into automated
analyzers). Further reduction of phlebotomy-associated
blood loss can be achieved by using closed in-line flush
blood sampling devices for arterial (and central) lines
(Koch et al. 2015; Ranasinghe and Freeman 2014; Fischer
et al. 2014; Mukhopadhyay et al. 2010) (level B).
Reduction of surgery-related blood loss starts from the
preoperative stage with appropriate cessation strategies
for anticoagulation and antiplatelet therapy (level C).
Intraoperative approaches such as advanced anesthetic
and surgical techniques with meticulous hemostasis in-
cluding minimally invasive surgery, laparoscopic surgery,
judicious use of diathermy dissection, physicians’ mind-
fulness regarding limiting blood loss, and application of
topical hemostatic agents (Shander et al. 2014b; Menkis
et al. 2012; Emilia et al. 2011; Anastasiadis et al. 2016)
(level B).
Advanced perioperative coagulation monitoring is cru-
cial for avoiding unnecessary blood loss. Adequate co-
agulation management needs to be a precondition
before RBC transfusion is considered. In this respect, the
use of a coagulation algorithm is recommended (Weber
et al. 2012; Weber et al. 2014), encompassing preopera-
tive assessment (Munoz et al. 2016) and ensuring basic
conditions for hemostasis (e.g., temperature, calcium,
pH), reversal of anticoagulants, point-of-care diagnostics
in bleeding (e.g., coagulopathic) patients (if available),
and optimized coagulation management with the use of
clotting factor concentrates (Kozek-Langenecker et al.
2013a; Kozek-Langenecker 2014; Meybohm et al. 2013;
Weber et al. 2013) (level B). To reduce surgical blood
loss, tranexamic acid should be used unless contraindi-
cated (Perel et al. 2013; Ker et al. 2013) (level A).
The use of intraoperative autologous blood collection
and re-transfusion (cell salvage) should be standardized
including indications and contraindications (Carless et
al. 2010). The use of (washed) cell recovery is highly
recommended in surgical settings where blood loss is
routinely or anticipated over 500 ml as it reduces the
rate of exposure to allogeneic RBC, risk of infection,
and length of hospital stay (Meybohm et al. 2016c)
(level A).
Optimal blood component use with patient-centered
clinical decision support
In order to optimize utilization of allogeneic blood prod-
ucts/components and to identify the ordering physician, it
is beneficial to adopt a physician order entry with a clin-
ical decision support based on electronic medical records
(Goodnough et al. 2014a; Oliver et al. 2014) (level B).
Thereby, indication for transfusion considering patient-
specific factors (e.g., age, diagnosis, co-morbidity, surgical
or non-surgical setting), signs/symptoms of acute anemia,
laboratory values (e.g., hemoglobin), presence or absence
of bleeding, and physiologic factors (e.g., oxygenation,
hemodynamic status) can be confirmed with required
checkboxes (Goodnough et al. 2016).
Patient’s informed consent should be obtained prior
transfusion of allogeneic blood products (components).
In emergency cases where it is not possible to obtain
consent, patient should be informed as soon as possible
after transfusion. A hand-written or computer-generated
forms (ideally a separate consent form) should be used
that is comprehensive and includes a detailed outline of
transfusion benefits, risks, and alternatives (ISBT ethic
code for blood donation and transfusion (International
Society of Blood Transfusion 2000)). It is necessary to
effectively communicate the risks and benefits of the
various potential interventions and to decide on the
right course of action together with the patient. It may
further be recommended that any transfusion of allogen-
eic blood products (components) should be mentioned
in the discharge summary. The patient’s own preferences
and values should be considered when developing a
medical plan (level C).
Conclusions
To enable any hospital to reduce both anemia preva-
lence and anemia-related unnecessary blood transfusion,
here, we provide simple, cost-effective, best-practice,
feasible, and evidence-based measure recommendations
developed with reference to existing best practice guide-
lines. As the level of evidence is still low for some
recommendations, we suggest that further studies are
needed to elucidate the potential role of these PBM
measures.
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